Addressing cardiovascular disease in patients with renal disease

It is well-established that patients with renal disease are at increased risk of cardiovascular disease (CVD) death. Despite better understanding of CVD in endstage renal disease (ESRD) patients and more rigid guidelines addressing the major risk factors for CVD in this population, CVD continues to...

Full description

Saved in:
Bibliographic Details
Published inEthnicity & disease Vol. 12; no. 4; p. S3
Main Authors Crook, Errol D, Washington, David O
Format Journal Article
LanguageEnglish
Published United States 2002
Subjects
Albuminuria - complications
Cardiovascular Diseases - complications
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Humans
Hyperlipidemias - complications
Hypertension - complications
Kidney Failure, Chronic - complications
Kidney Failure, Chronic - mortality
Risk Factors
United States
United States
Online AccessGet more information

Cover

More Information
Summary:It is well-established that patients with renal disease are at increased risk of cardiovascular disease (CVD) death. Despite better understanding of CVD in endstage renal disease (ESRD) patients and more rigid guidelines addressing the major risk factors for CVD in this population, CVD continues to be the number one cause of death in patients with ESRD. Moreover, higher rates of CVD are seen in patients with moderate, and even mild, renal dysfunction and in patients with albuminuria (micro and macroscopic). Few studies with CVD endpoints have included patients with renal disease. There is sufficient evidence to support appropriate blood pressure reduction as having a beneficial effect on CVD morbidity and mortality in patients with renal disease (especially for patients with diabetes). Data supporting the benefit of modification of other CVD risk factors is not as strong, but current recommendations do stress aggressive control of lipids, smoking cessation, and maintenance of adequate nutritional status. Inclusion of patients with renal disease in studies with CVD endpoints is necessary. Until then, it is generally recommended that CVD risk stratification and modification strategies be applied to this high-risk population.
ISSN:1049-510X